CRP and metabolic dysfunction-associated steatohepatitis: Gemcabene 100 and 300 mg/kg treated groups showed a significant reduction in CRP mRNA levels (0.6 ± 0.1 and 0.5 ± 0.1, respectively) compared with the vehicle-treated NASH group (1.0 ± 0.2), consistent with the observed clinical reduction of plasma CRP with gemcabene [17].